2-amino-5-methylsulphonyl-benzimidazole | 30486-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-amino-5-methylsulphonyl-benzimidazole
• 英文别名: 5-(methylsulfonyl)-1H-benzo[d]imidazol-2-amine；5-methanesulfonyl-1(3)H-benzoimidazol-2-ylamine；2-amino-5-methylsulfonylbenzimidazole；6-methylsulfonyl-1H-benzimidazol-2-amine
• CAS: 30486-70-5
• 化学式: C₈H₉N₃O₂S
• 分子量: 211.244
• InChiKey: PLXWDSFSWSALBY-UHFFFAOYSA-N

物化性质

• 沸点：
  564.5±56.0 °C(Predicted)
• 密度：
  1.518±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  97.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2,3 -二氢-1-呋喃-5-基)-1,3-噻唑-4-羧酸 、 2-amino-5-methylsulphonyl-benzimidazole 在 4-二甲氨基吡啶 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以51%的产率得到2-(2,3-dihydrobenzofuran-5-yl)-N-(5-(methylsulfonyl)-1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide
  参考文献：
  名称：

  [EN] 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS
  [FR] COMPOSÉS 2,3-DIHYDROBENZOFURAN-5-YL UTILISÉS COMME INHIBITEURS DE KINASES DYRK

  摘要：

  公开号：

  WO2014202638A9
• 作为产物：
  描述：

  2-硝基-4-甲砜基氯苯 在 氨 、 硝酸 、 一水合肼 作用下， 以 乙醇 、 硫酸 、 水 为溶剂， 生成 2-amino-5-methylsulphonyl-benzimidazole
  参考文献：
  名称：

  Substituted 1-sulfonylbenzimidazoles

  摘要：

  某些1-磺酰基-2,5(6)-取代苯并咪唑化合物可用作抗病毒药物。

  公开号：

  US04018790A1

文献信息

• 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS
  申请人：4SC DISCOVERY GMBH

  公开号：US20160137637A1

  公开（公告）日：2016-05-19

  The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R 1 , R 2 , R 3 , R 4 , R A , X 1 , and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.

  本发明涉及以下公式（I）的化合物，其生理学功能衍生物或盐，其中R1，R2，R3，R4，RA，X1和A组，以及变量n，m和p的详细信息在此进一步说明。在另一方面，本发明提供了制备它们的方法，它们的医学用途和包含所述化合物、生理学功能衍生物、溶剂化物或其盐的制药组合物。
• 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors
  申请人：4SC DISCOVERY GMBH

  公开号：US10005769B2

  公开（公告）日：2018-06-26

  The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R1, R2, R3, R4, RA, X1, and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.

  本发明涉及下式（I）化合物、其生理功能衍生物或盐类，其中基团 R1、R2、R3、R4、RA、X1 和 A 以及变量 n、m 和 p 在此进一步详述。 在另一方面，本发明提供了包含上述化合物、其生理功能衍生物、溶液或盐的制备方法、医疗用途和药物组合物。
• Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents
  作者：Shahul Hameed P、Murugan Chinnapattu、Gajanan Shanbag、Praveena Manjrekar、Krishna Koushik、Anandkumar Raichurkar、Vikas Patil、Sandesh Jatheendranath、Suresh S. Rudrapatna、Shubhada P. Barde、Nikhil Rautela、Disha Awasthy、Sapna Morayya、Chandan Narayan、Stefan Kavanagh、Ramanatha Saralaya、Sowmya Bharath、Pavithra Viswanath、Kakoli Mukherjee、Balachandra Bandodkar、Abhishek Srivastava、Vijender Panduga、Jitender Reddy、K. R. Prabhakar、Achyut Sinha、María Belén Jiménez-Díaz、María Santos Martínez、Iñigo Angulo-Barturen、Santiago Ferrer、Laura María Sanz、Francisco Javier Gamo、Sandra Duffy、Vicky M. Avery、Pamela A. Magistrado、Amanda K. Lukens、Dyann F. Wirth、David Waterson、V. Balasubramanian、Pravin S. Iyer、Shridhar Narayanan、Vinayak Hosagrahara、Vasan K. Sambandamurthy、Sreekanth Ramachandran

  DOI：10.1021/jm500535j

  日期：2014.7.10

  Whole-cell high-throughput screening of the AstraZeneca compound library against the asexual blood stage of Plasmodium falciparum (Pf) led to the identification of amino imidazoles, a robust starting point for initiating a hit-to-lead medicinal chemistry effort. Structure-activity relationship studies followed by pharmacokinetics optimization resulted in the identification of 23 as an attractive lead with good oral bioavailability. Compound 23 was found to be efficacious (ED90 of 28.6 mg.kg(-1)) in the humanized P. falciparum mouse model of malaria (Pf/SCID model). Representative compounds displayed a moderate to fast killing profile that is comparable to that of chloroquine. This series demonstrates no cross-resistance against a panel of Pf strains with mutations to known antimalarial drugs, thereby suggesting a novel mechanism of action for this chemical class.
• 2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε
  作者：Joachim Bischof、Johann Leban、Mirko Zaja、Arnhild Grothey、Barbara Radunsky、Olaf Othersen、Stefan Strobl、Daniel Vitt、Uwe Knippschild

  DOI：10.1007/s00726-012-1234-x

  日期：2012.10

  In this study we identified two heterocyclic compounds (5 and 6) as potent and specific inhibitors of CK1 delta (IC50 = 0.040 and 0.042 mu M, respectively). Whereas compound 5 exhibited fivefold higher affinity towards CK1 delta than to CK1 epsilon (IC50 CK1 epsilon = 0.199 mu M), compound 6 also inhibited CK1 epsilon (IC50 = 0.0326 mu M) in the same range as CK1 delta. Selected compound 5 was screened over 442 kinases identifying 5 as a highly potent and selective inhibitor of CK1 delta. X-ray analysis of 5 bound to CK1 delta demonstrated its binding mode. In addition, characterization of 5 and 6 in a cell biological approach revealed the ability of both compounds to inhibit proliferation of tumor cell lines in a dose and cell line specific manner. In summary, our optimizations lead to the development of new highly selective CK1 delta and epsilon specific inhibitors with biological activity.
• US4018790A
  申请人：——

  公开号：US4018790A

  公开（公告）日：1977-04-19